Osteogenesis imperfecta is characterised by low bone mineral density, bone fragility, fractures and deformity. We present five such children treated with intravenous pamidronate, which resulted in a decrease of fracture rate and increase in spinal bone mineral density.
LindahlKÅströmERubinCJ, et al.Genetic epidemiology, prevalence, and genotype–phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet2015; 23: 1042–1050.
2.
BarnesAMChangWMorelloR, et al.Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med2006; 355: 2757–2764.
3.
LindahlKKindmarkARubinCJ, et al.Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with pamidronate. Bone2016; 87: 11–18.
4.
GlorieuxFHBishopNJPlotkinH, et al.Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med1998; 339: 947−952–947−952.
5.
ShahIJohariA. Oral bisphosphonate treatment for osteogenesis imperfecta – an Indian perspective. Ann Trop Pediatr2007; 27: 39–43.
6.
BachrachLKWardLM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab2009; 94: 400–409.
7.
DiMeglioLAPeacockM. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res2006; 21: 132–140.
8.
LandCRauchFMunnsCF, et al.Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone2006; 39: 901–906.
9.
DwanKPhillipiCASteinerRD, et al.Bisphosphonate therapy for osteogenesis imperfecta. Cochr Database Syst Rev2014; 7: CD005088–CD005088.
10.
PalomoTFassierFOuelletJ, et al.Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res2015; 30: 2150–2157.
